Delap Wealth Advisory LLC Invests $454,000 in Natera, Inc. (NASDAQ:NTRA)

Delap Wealth Advisory LLC bought a new stake in Natera, Inc. (NASDAQ:NTRA) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 4,190 shares of the medical research company’s stock, valued at approximately $454,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. SG Americas Securities LLC increased its holdings in shares of Natera by 1,073.1% in the 2nd quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock valued at $7,118,000 after acquiring an additional 60,127 shares during the last quarter. Thematics Asset Management increased its stake in Natera by 3.1% in the fourth quarter. Thematics Asset Management now owns 90,232 shares of the medical research company’s stock valued at $5,652,000 after purchasing an additional 2,738 shares during the last quarter. Crestline Management LP increased its stake in Natera by 16.0% in the fourth quarter. Crestline Management LP now owns 65,070 shares of the medical research company’s stock valued at $4,076,000 after purchasing an additional 8,997 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Natera by 15.1% during the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock worth $6,810,000 after purchasing an additional 9,781 shares in the last quarter. Finally, Perceptive Advisors LLC lifted its position in shares of Natera by 289.7% during the 4th quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock worth $53,258,000 after buying an additional 632,047 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Morgan Stanley increased their target price on shares of Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. TD Cowen lifted their target price on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. StockNews.com cut Natera from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th. BTIG Research lifted their price target on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, Piper Sandler reissued an “overweight” rating and issued a $150.00 price objective on shares of Natera in a report on Friday, September 13th. One research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $120.07.

Natera Trading Up 0.5 %

NASDAQ NTRA opened at $127.78 on Friday. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $15.69 billion, a P/E ratio of -40.96 and a beta of 1.53. Natera, Inc. has a 52-week low of $36.90 and a 52-week high of $132.01. The firm has a 50-day moving average price of $114.45 and a 200 day moving average price of $105.43.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company had revenue of $413.35 million for the quarter, compared to analysts’ expectations of $343.00 million. During the same quarter in the previous year, the firm posted ($0.97) EPS. The firm’s quarterly revenue was up 58.1% on a year-over-year basis. Equities research analysts expect that Natera, Inc. will post -1.96 EPS for the current year.

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 5,024 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the transaction, the chief executive officer now owns 195,686 shares in the company, valued at approximately $25,141,737.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Michael Burkes Brophy sold 4,983 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $108.37, for a total value of $540,007.71. Following the sale, the chief financial officer now owns 75,059 shares in the company, valued at approximately $8,134,143.83. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 5,024 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $128.48, for a total value of $645,483.52. Following the completion of the sale, the chief executive officer now owns 195,686 shares in the company, valued at approximately $25,141,737.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 93,921 shares of company stock worth $10,551,281. Company insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.